Powerpack

Unlock full stockrow access for only $9.90/month and boost yourself as an investor.

  • Full quarterly history

    Every quarter and TTM period we hold, not just the last 12.

  • Analyst estimates

    Three years of forward estimates and dividend forecasts.

  • Unlimited screener

    All results, unlimited saved screens, email when a screen changes.

  • Unlimited Excel

    Full workbooks and screener exports.

  • Unlimited follows

See Powerpack
Screener Weekly Summary Pricing

NeuroOne Medical Technologies Corporation NMTC

Healthcare  —  Medical Devices
1.33 0.00 0.00% as of 25 Sep
Market cap
$12.1M
P/E
0.0×
Revenue Champion (3y) Insider Buys (last 12m)
Growth Flags show if company had growth for consecutive years,
Insider Buys alert about insiders buying in the last 12 month
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

NeuroOne Medical Technologies Corporation (NMTC) Business Profile

Updated before January 2025

Company Overview

NeuroOne Medical Technologies Corporation (NMTC) is a pioneering medical technology company focused on developing and commercializing innovative solutions for neurological disorders. Founded in 2016, the company is headquartered in Eden Prairie, Minnesota, USA. NMTC was established with the mission to revolutionize the treatment of neurological conditions by providing advanced, minimally invasive solutions that improve patient outcomes and reduce healthcare costs.

The company is led by a team of seasoned professionals with extensive experience in the medical device and healthcare industries. Dave Rosa serves as the President and Chief Executive Officer, bringing decades of leadership and expertise in medical technology. The leadership team also includes Mark Christianson as Chief Financial Officer and Dr. Kip Ludwig as Chief Scientific Officer, among others. Together, they drive NMTC’s vision of transforming neurological care through cutting-edge technology.

Core Business Segments

NeuroOne Medical Technologies Corporation operates primarily in the field of neurology, offering a range of products and solutions designed to address various neurological conditions. The company’s core business segments include:

1. Electrode Technology

NMTC specializes in the development of high-definition, minimally invasive electrode technology for brain and spinal cord applications. These electrodes are designed for diagnostic, therapeutic, and monitoring purposes. Key products include:

  • Evo® Cortical Electrodes: These electrodes are used for recording, monitoring, and stimulating brain activity. They are designed to provide high-resolution imaging and are thinner and more flexible than traditional electrodes, ensuring patient comfort.
  • Evo® sEEG Electrodes: These are stereoelectroencephalography (sEEG) electrodes used for minimally invasive brain mapping and seizure localization in patients with epilepsy.

2. Neuromodulation Devices

The company is actively developing neuromodulation devices aimed at treating chronic neurological conditions such as epilepsy, Parkinson’s disease, and chronic pain. These devices leverage electrical stimulation to modulate neural activity and improve patient outcomes.

3. Diagnostic and Monitoring Solutions

NMTC also offers advanced solutions for diagnosing and monitoring neurological disorders. These include systems that integrate with their electrode technology to provide real-time data and insights for clinicians.

Business Model

NeuroOne Medical Technologies Corporation operates on a business model that integrates product innovation, strategic partnerships, and revenue generation through product sales and licensing agreements. The company focuses on:

  • Product Development: NMTC invests heavily in research and development to create cutting-edge neurological devices that address unmet clinical needs.
  • Strategic Partnerships: The company collaborates with leading healthcare institutions, research organizations, and industry partners to accelerate product development and commercialization.
  • Revenue Streams: NMTC generates revenue through the sale of its electrode technology and neuromodulation devices. Additionally, the company licenses its technology to other medical device manufacturers, creating an additional revenue stream.

Strategic Direction

NeuroOne Medical Technologies Corporation is committed to advancing neurological care through innovation and strategic growth. Key elements of the company’s strategic direction include:

  • Product Portfolio Expansion: NMTC aims to expand its product portfolio by developing new electrode technologies and neuromodulation devices. The company is also exploring opportunities in emerging areas such as brain-computer interfaces and artificial intelligence-driven diagnostics.
  • Global Market Penetration: The company plans to increase its presence in international markets by establishing distribution networks and partnerships with global healthcare providers.
  • Sustainability Goals: NMTC is dedicated to minimizing its environmental impact by adopting sustainable manufacturing practices and reducing waste in its operations.
  • Clinical Research and Trials: The company continues to invest in clinical research to validate the efficacy and safety of its products, ensuring regulatory compliance and market acceptance.

Competitive Landscape

NeuroOne Medical Technologies Corporation operates in a highly competitive market, facing competition from established medical device companies and emerging startups. Key competitors include:

  • Medtronic: A global leader in medical technology, offering a wide range of neuromodulation devices and electrode technologies.
  • Boston Scientific: Known for its innovative neuromodulation solutions for chronic pain and neurological disorders.
  • NeuroPace: Specializes in responsive neurostimulation systems for epilepsy treatment.
  • Blackrock Neurotech: Focuses on brain-computer interface technology and high-resolution neural recording devices.

Despite the competition, NMTC differentiates itself through its focus on minimally invasive solutions and high-definition electrode technology.

Risk Factors

Like any medical technology company, NMTC faces several risks that could impact its operations and financial performance. Key risk factors include:

  • Regulatory Challenges: The company’s products must comply with stringent regulatory requirements, and delays in obtaining approvals could hinder product launches.
  • Market Dependence: NMTC relies heavily on the success of its electrode technology and neuromodulation devices. Any decline in demand for these products could affect revenue.
  • Supply Chain Disruptions: The company is vulnerable to disruptions in its supply chain, which could delay production and delivery of its products.
  • Competition: Intense competition from established players and new entrants could impact NMTC’s market share and pricing power.
  • Financial Constraints: As a relatively young company, NMTC may face challenges in securing funding for research, development, and commercialization efforts.

Recent Developments

NeuroOne Medical Technologies Corporation has made significant strides in recent years, including:

  • FDA Approvals: The company received FDA clearance for its Evo® Cortical and sEEG Electrodes, paving the way for commercialization in the U.S. market.
  • Partnerships: NMTC entered into strategic partnerships with leading healthcare institutions to advance clinical research and product development.
  • Product Innovations: The company launched next-generation electrode technologies with improved flexibility, durability, and imaging capabilities.
  • Global Expansion: NMTC has begun exploring opportunities in international markets, including Europe and Asia, to expand its customer base.

Investment Considerations

Investors considering NeuroOne Medical Technologies Corporation should weigh the following strengths and risks:

Strengths

  • Innovative Technology: NMTC’s high-definition, minimally invasive electrode technology sets it apart from competitors.
  • Growing Market: The global market for neurological devices is expanding, driven by increasing prevalence of neurological disorders.
  • Strong Leadership: The company is led by an experienced team with a proven track record in the medical device industry.
  • Regulatory Approvals: Recent FDA clearances validate the safety and efficacy of NMTC’s products.

Risks

  • Early-Stage Company: As a relatively young company, NMTC faces challenges related to scaling operations and achieving profitability.
  • Regulatory and Market Risks: Delays in regulatory approvals or changes in market dynamics could impact the company’s growth.
  • Competition: Intense competition from established players poses a risk to NMTC’s market position.

Conclusion

NeuroOne Medical Technologies Corporation is a promising player in the medical technology industry, with a strong focus on innovation and improving neurological care. The company’s advanced electrode technology and neuromodulation devices position it well to address the growing demand for minimally invasive solutions. While challenges remain, NMTC’s strategic direction, recent achievements, and commitment to innovation provide a solid foundation for future growth. As the company continues to expand its product portfolio and global presence, it is poised to make a significant impact in the field of neurology.